Navidea Biopharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, NAVB, Navidea Biopharmaceuticals Inc, priceseries

Navidea Biopharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.79
Close
0.81
High
0.90
Low
0.79
Previous Close
0.81
Daily Price Gain
0.00
YTD High
1.27
YTD High Date
Jan 4, 2022
YTD Low
0.72
YTD Low Date
Feb 4, 2022
YTD Price Change
-0.39
YTD Gain
-32.50%
52 Week High
2.50
52 Week High Date
Mar 10, 2021
52 Week Low
0.72
52 Week Low Date
Feb 4, 2022
52 Week Price Change
-1.24
52 Week Gain
-60.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 31. 2017
9.22
Jun 16. 2017
10.01
12 Trading Days
8.60%
Link
LONG
Sep 27. 2017
8.19
Oct 11. 2017
8.62
10 Trading Days
5.28%
Link
LONG
Sep 14. 2018
3.60
Sep 28. 2018
4.67
10 Trading Days
29.74%
Link
LONG
Dec 24. 2019
1.11
Jan 21. 2020
1.44
17 Trading Days
29.61%
Link
LONG
Apr 27. 2020
0.76
Jun 11. 2020
2.97
32 Trading Days
290.39%
Link
LONG
Jul 17. 2020
4.15
Jul 31. 2020
4.40
10 Trading Days
5.94%
Link
LONG
Jun 4. 2021
1.78
Jun 21. 2021
1.89
11 Trading Days
5.97%
Link
Company Information
Stock Symbol
NAVB
Exchange
NYSE MKT
Company URL
http://www.navidea.com
Company Phone
6147937500
CEO
Mike M. Goldberg
Headquarters
Ohio
Business Address
4995 BRADENTON AVENUE, SUITE 240, DUBLIN, OH 43017
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000810509
About

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company offers Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its neurological development programs include NAV4694, an Fluorine-18 labeled positron emission tomography imaging agent, which is used as an aid the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment; and NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading